BiotechTube

dasatinib + dasatinib

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myeloid Leukemia, Chronic, Accelerated Phase

Conditions

Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Trial Timeline

Jun 1, 2005 → Jun 1, 2013

NCT ID
NCT00123487

About dasatinib + dasatinib

dasatinib + dasatinib is a phase 3 stage product being developed by Bristol Myers Squibb for Myeloid Leukemia, Chronic, Accelerated Phase. The current trial status is completed. This product is registered under clinical trial identifier NCT00123487. Target conditions include Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive.

What happened to similar drugs?

10 of 20 similar drugs in Myeloid Leukemia, Chronic, Accelerated Phase were approved

Approved (10) Terminated (4) Active (8)
✅Venetoclax + AzacitidineAbbVieApproved
✅Venetoclax + Azacitidine + AzacitidineAbbVieApproved
✅NilotinibNovartisApproved
✅NilotinibNovartisApproved
✅Nilotinib 300 mg.NovartisApproved
✅NilotinibNovartisApproved
✅AMN107NovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT00482703Phase 1/2Completed
NCT00385580Phase 2Completed
NCT00371254Phase 2Completed
NCT00123487Phase 3Completed

Competing Products

20 competing products in Myeloid Leukemia, Chronic, Accelerated Phase

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
11
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
42
TERN-701Terns PharmaceuticalsPhase 1/2
36
PRGN-3006 T CellsPrecigenPhase 1
27
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
15
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
ZN-d5Zentalis PharmaceuticalsPhase 1
19
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
26
TomivosertibeFFECTOR TherapeuticsPhase 1
23
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
40
Quizartinib High Dose + Quizartinib Low DoseDaiichi SankyoPhase 2
42
Decitabine + Quizartinib + VenetoclaxDaiichi SankyoPhase 1/2
39
MilademetanDaiichi SankyoPhase 1
29
Quizartinib + Treatment according to Physician's Choice + Standard of Care ChemotherapyDaiichi SankyoPhase 3
32
Quizartinib + Cytarabine + Idarubicin + DaunorubicinDaiichi SankyoPhase 1
29
AC220Daiichi SankyoPhase 2
35
PLX3397 + PLX3397Daiichi SankyoPhase 1/2
32
QuizartinibDaiichi SankyoPhase 2
35
QuizartinibDaiichi SankyoPhase 1
29
Quizartinib + Fludarabine + Cytarabine + Idarubicin + glycosylated G-CSFDaiichi SankyoPhase 1/2
28